FibroGen (NASDAQ:FGEN) Releases Earnings Results, Beats Estimates By $0.02 EPS

FibroGen (NASDAQ:FGEN) released its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.02, Briefing.com reports. FibroGen had a net margin of 11.81% and a return on equity of 7.33%. The firm had revenue of $33.17 million for the quarter, compared to analysts’ expectations of $31.61 million. During the same quarter last year, the business posted ($0.50) earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year.

Shares of NASDAQ:FGEN traded up $2.54 on Wednesday, hitting $46.78. 650,865 shares of the company’s stock were exchanged, compared to its average volume of 731,732. FibroGen has a 12 month low of $32.33 and a 12 month high of $61.23. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -45.42 and a beta of 1.84. The business’s 50 day simple moving average is $39.47 and its two-hundred day simple moving average is $41.32. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.01 and a quick ratio of 8.95.

Several research firms have commented on FGEN. TheStreet raised shares of FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. Zacks Investment Research lowered shares of FibroGen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 14th. BidaskClub raised shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. ValuEngine raised shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. Finally, Mizuho reaffirmed a “buy” rating and set a $72.00 price objective on shares of FibroGen in a research note on Monday, November 18th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. FibroGen presently has a consensus rating of “Buy” and an average target price of $58.33.

In related news, SVP Christine Chung sold 5,625 shares of FibroGen stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $34.74, for a total value of $195,412.50. Following the completion of the sale, the senior vice president now directly owns 145,253 shares in the company, valued at $5,046,089.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Pat Cotroneo sold 3,201 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $41.38, for a total transaction of $132,457.38. Following the completion of the transaction, the chief financial officer now owns 244,432 shares of the company’s stock, valued at $10,114,596.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,495 shares of company stock valued at $1,596,769. Corporate insiders own 7.83% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Story: Why does a company issue an IPO?

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.